1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Commentary: Private investment round-up for April 2009

 
• By Simon Varcoe

Investments in private pharmaceutical and biotech companies slumped by 24% in April, with the market being once again dominated by US companies, a Scrip analysis has found.

Investments in private pharmaceutical and biotech companies slumped by 24% in April, with the market being once again dominated by US companies, a Scrip analysis has found.

A total of 12 companies raised $219.3 million, one fewer than in March.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

Boehringer Sees Opportunities For Jascayd In Evolving China IPF Landscape

 
• By Xu Hu

Boehringer’s PDE4B inhibitor Jascayd was approved for IPF in China on Oct. 22, marking its second nod globally soon after the US. The German firm discusses with Scrip the opportunities and challenges in this market.

Walmsley Signs Off With GSK Growth Upgrade

 
• By Andrew McConaghie

The departing CEO announced improved full-year sales and profit forecasts before handing over to Luke Miels in January; he will then have to deliver on GSK’s upgraded forecast of £40bn revenues in 2031.

GSK Expands Respiratory Pipeline With siRNA Pact

 
• By Andrew McConaghie

Its licensing deal with Empirico for EMP-012 opens up the potential to treat a broader range of COPD patients compared with existing therapies.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

More from Therapeutic Category

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.

Lilly Plans Phase III Trials After Positive Results From Amylin Drug Eloralintide

 
• By Alaric DeArment

The drugmaker presented positive data from its Phase II study at ObesityWeek that help validate the amylin class overall, which includes more than a dozen entrants.